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Human serum albumin (HSA) is one of the most frequent treat-
ments in patients with decompensated cirrhosis. Prevention of
paracentesis-induced circulatory dysfunction, prevention of
type-1 HRS associated with bacterial infections, and treatment
of type-1 hepatorenal syndrome are the main indications. In
these indications treatment with HSA is associated with improve-
ment in survival. Albumin is a stable and very ﬂexible molecule
with a heart shape, 585 residues, and three domains of similar
size, each one containing two sub-domains. Many of the physio-
logical functions of HSA rely on its ability to bind an extremely
wide range of endogenous and exogenous ligands, to increase
their solubility in plasma, to transport them to speciﬁc tissues
and organs, or to dispose of them when they are toxic. The chem-
ical structure of albumin can be altered by some speciﬁc
processes (oxidation, glycation) leading to rapid clearance and
catabolism. An outstanding feature of HSA is its capacity to bind
lipopolysaccharide and other bacterial products (lipoteichoic
acid and peptidoglycan), reactive oxygen species, nitric oxide
and other nitrogen reactive species, and prostaglandins. Binding
to NO and prostaglandins are reversible, so they can be trans-
ferred to other molecules at different sites from their synthesis.
Through these functions, HSA modulates the inﬂammatory reac-
tion. Decompensated cirrhosis is a disease associated systemic
inﬂammation, which plays an important role in the pathogenesis
of organ or system dysfunction/failure. Although, the beneﬁcial
effects of HAS have been traditionally attributed to plasmaJournal of Hepatology 20
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decompensated cirrhosis: Background and current indications
History
Diuretics, antibiotics, and HSA are the most frequently used
treatments for the management of patients with cirrhosis.
According to the CANONIC study database [1], a prospective
European investigation in 1348 patients with decompensated cir-
rhosis, HSA was indicated in 60% of the patients during hospital
admission (Table 1).
The history of HSA started in 1940, when a long-term stable
substitute of blood was required by the US military authorities
to treat shock on the battleﬁeld during the World War II [2]. It
was used for ﬁrst time in December 1941 in seven severely
burned sailors after the attack on Pearl Harbor. At that period,
the association of portal hypertension, hypoalbuminemia, and
ascites was already known. Not surprisingly, ascites was one of
the ﬁrst indications of HSA. Three studies published between
1946 and 1949 assessing the effect of short- and long-term i.v.
infusion of HSA in cirrhotic patients with ascites deﬁned the ﬁrst
indications of HSA in cirrhosis [3–5]. Serum albumin concentra-
tion and urine volume increased in most patients. Peripheral
edema also improved. However, only some patients showed
improvement of ascites. First indication of HSA was, therefore,
hypoalbuminemia in patients treated by frequent paracentesis.
The introduction of spironolactone and furosemide in the early
1960’s and the article by Hecker and Sherlock [6] ﬁrst describing
hepatorenal syndrome (HRS) lead to great changes in the man-
agement of ascites. The concept that paracentesis could be fol-
lowed by rapid reformation of ascites and renal failure
extended rapidly through the medical community and therapeu-
tic paracentesis was formally proscribed. Only in 10% of patients
not responding to diuretics (refractory ascites) was HSA pre-
scribed to increase the plasma volume and diuretic effect [7]. In
the 1970’s LeVeen designed the ﬁrst peritoneo-venous shunt
[8]. It consisted in a multi-perforated intra-peritoneal tube con-
nected to a unidirectional valve and to a second tube that subcu-
taneously reached the superior vena cava through the internal14 vol. 61 j 396–407
Table 1. Use of albumin in patients with acute decompensation of cirrhosis in Europe. Results from the CANONIC study database.
Patients with hospitalization follow-up* Patients receiving albumin during hospitalization
Patients (n) 699 425 (60.8%)
Bacterial infections (n) 398 (56.9%) 152 (38.2%)
SBP (n) 107 (15.3%) 53 (49.5%)
Non-SBP infections (n) 291 (41.6%) 65 (22.3%)
Paracentesis (n) 291 (41.6%) 225 (77.3%)
<5 L (n) 158 (22.6%) 107 (67.7%)
5-9 L (n) 137 (19.5%) 123 (89.8%)
>9 L (n) 55 (7.8%) 51 (92.7%)
HRS (n) 179 (25.6%) 75 (41.9%)
⁄The CANONIC study was made in 1348 patients. The table only includes patients with hospitalization follow-up. There were patients with more than one complication
requiring albumin administration.
JOURNAL OF HEPATOLOGYjugular vein. The positive abdominal pressure and the negative
intra-thoracic pressure facilitated the opening of the valve and
the continuous passage of ascites into the circulation. LeVeen
shunt was widely used in the management of refractory ascites
for more than a decade. Following the introduction of LeVeen
shunt, HSA disappeared from the therapeutic armamentarium
of cirrhosis for more than a decade.
Current indications of albumin
Management of ascites
In 1988 a Spaniard inter-hospital group [9] demonstrated that
paracentesis, if performed in association to HSA, was an effective
and safe therapy of ascites. They compared repeated large vol-
ume paracentesis (4 liters/day) associated with HSA (8 g per liter
of ascitic ﬂuid removed) vs. diuretics. The incidence of renal
impairment, hyponatremia and encephalopathy was signiﬁcantly
lower in the paracentesis group. No signiﬁcant change in plasma
renin activity was observed indicating no impairment in effective
blood volume. Survival probability was similar in both groups. In
a second investigation, total paracentesis (complete removal of
ascites in only one tap) associated with HSA was also found to
be safe [10]. Treatment of ascites was therefore considerably sim-
pliﬁed. Instead of requiring 2–4 weeks in hospital to compensate
a tense ascites with diuretics, patients could be managed by par-
acentesis in a single day hospitalization regime [11]. Paracentesis
associated with HSA was subsequently compared to peritoneo-
venous shunting in patients with refractory ascites [12]. Perito-
neo-venous shunting was superior to paracentesis in the long-term
control of ascites. However, due to the high rate of complications
associated with the prosthesis, the total time in hospital and the
probability of survival was similar with both treatments. Based
on these data, paracentesis plus HSA was considered the treat-
ment of choice for tense ascites.
When paracentesis is performed without HSA or if HSA is
substituted by synthetic plasma expanders, a high proportion of
patients develop marked activation of the renin-angiotensin sys-
tem, a feature known as paracentesis-induced circulatory dys-
function (PICD) [13–15]. The prevalence of PICD in patients not
receiving volume expansion is 70%. In patients receiving dextran
or polygeline it is also high (37.8%). PICD is due to an accentua-
tion of the arterial vasodilation already present in cirrhosis and
a lack of appropriated cardiac response [16–18] (Fig. 1). PICD,
although asymptomatic, is a serious complication. It is not spon-
taneously reversible and is associated with shorter time to hospi-
tal readmission, higher incidence of renal failure, and shorter
probability of survival [15]. A recent meta-analysis (17 trials,Journal of Hepatology 2011,225 patients) comparing HSA vs. alternative treatments (no vol-
ume expansion, synthetic plasma expanders or vasoconstrictors)
has shown that HSA signiﬁcantly reduces the incidence of PICD
and mortality [19].
Prevention of type-1 HRS associated with spontaneous bacterial
peritonitis (SBP)
Despite infection resolution, 20–40% of patients with SBP develop
type-1 HRS in relation to arterial vasodilation, acute impairment
in cardiac function, and compensatory activation of the renin-
angiotensin and sympathetic nervous systems [20–23] (Table 2).
Type 1 HRS also develops in cirrhotic patients with other type of
bacterial infections although the prevalence is lower [24–26]. The
reason why SBP is such a frequent precipitating event of type-1
HRS is multifactorial. First, an exaggerated inﬂammatory
response to sepsis occurs in patients with cirrhosis and ascites
with an increase in plasma levels of cytokines 20-fold greater
than in individuals without cirrhosis [26]. This feature has also
been observed in experimental animals in which doses of bacte-
rial endotoxin that do not produce any change in systemic hemo-
dynamics in healthy rats, induce arterial hypotension and
increase the plasma levels of cytokines by 100-fold in rats with
cirrhosis and ascites [27]. Second, the inﬂammatory response to
bacterial infection persists for a longer duration in cirrhosis.
Finally, patients with cirrhosis and ascites already have severe
impairment in cardio-circulatory and renal function, which pre-
dispose these patients to further deterioration in organ function
[28]. In support to this contention, patients with SBP who have
increased serum creatinine concentration or dilutional hypona-
tremia prior to infection, and those with intense inﬂammatory
response (high concentration of polymorphonuclear leukocytes,
tumor-necrosis-factor alpha and interleukin-6 in plasma, and
ascitic ﬂuid) are at high risk of developing type-1 HRS
[23,29,30]. If untreated, type-1 HRS in patients with SBP is asso-
ciated with a mortality rate approaching 100% [31].
In 1999 we reported the use of HSA (1.5 g/kg b.wt. at infection
diagnosis and 1 g/kg b.wt. at the third day) in SBP [31]. HSA pre-
vented cardiovascular dysfunction and this was associated with a
dramatic decrease in the prevalence of type 1 HRS and hospital
mortality (10% in the HSA group and 30% in the control group).
A recent meta-analysis has conﬁrmed these ﬁndings [32].
Treatment of type-1 HR
The use of vasopressin analogs and HSA for the treatment of
type-1 HRS was based on two features. First, arterial vasodilation
in cirrhosis occurs in the splanchnic circulation and vasopressin
analogs act preferentially in this area [28]. Second, studies using4 vol. 61 j 396–407 397
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Fig. 1. Paracentesis-induced circulatory dysfunction in patients not receiving HSA. Relationship to changes in systemic vascular resistance. (A) Plasma renin activity
before and after therapeutic paracentesis in cirrhotic patients with ascites not receiving HSA. Plasma renin activity increased in most patients indicating the development of
paracentesis-induced circulatory dysfunction [13]. (B) Relationship between changes in systemic vascular resistance and of plasma renin activity. An inverse relationship
was observed indicating that circulatory dysfunction is related to arterial vasodilation [17].
Table 2. Effect of treatment with vasoconstrictors (ornipressin and terlipres-
sin) and i.v. albumin in type-1 HRS (n = 15).⁄
Baseline
(n = 15)
Day 7
(n = 9)
Day 14
(n = 7)
MAP (mmHg) 70 ± 8 77 ± 9 79 ± 12
PRA (ng/ml.h) 15 ± 15 2 ± 3 1 ± 1
NE (pg/ml) 1257 ± 938 550 ± 410 316 ± 161
Serum creatinine (mg/dl) 3 ± 1 2 ± 1 1 ± 1
GFR (ml/min) 9 ± 1 25 ± 2.5 41 ± 1.5
⁄Data obtained from [34,35].
MAP, mean arterial pressure; PRA, plasma renin activity; NE, plasma norepi-
nephrine concentration.
Table 3. Cardiovascular hemodynamics in 8 patients developing HRS after
spontaneous bacterial peritonitis.⁄
At SBP 
diagnosis
Following SBP
resolution
p value
Serum creatinine (mg/dl) 1.3 ± 0.6 2.5 ± 0.4 <0.02
BUN (mg/dl) 37.4 ± 9.5 81.2 ± 25.2 <0.02
MAP (mmHg) 83 ± 7 73 ± 8 <0.02
PRA (ng/ml.h) 18 ± 11 28 ± 12 <0.02
NE (pg/ml) 797 ± 226 1290 ± 415 <0.02
SVR (dyn.s.cm-5) 1137 ± 220 1268 ± 320 n.s.
CO (L/min) 5.7 ± 0.9 4.6 ± 0.7 <0.02
RAP (mmHg) 3.0 ± 3.0 4.6 ± 2.7 n.s.
PCWP (mmHg) 5.7 ± 4.0 7.4 ± 2.6 n.s.
HR (bpm) 93 ± 13 87 ± 9 n.s.
⁄Obtained from [21].
Mean time elapsed between measurement was 6 days.
BUN, blood urea nitrogen; MAP, mean arterial pressure; PRA, plasma renin
activity; NE, plasma norepinephrine concentration; SVR, systemic vascular
resistance; CO, cardiac output; RAP, right atrial pressure; PCWP, pulmonary
capillary wedged pressure; HR, heart rate.
Reviewhead-out water immersion, a procedure that expands the central
blood volume, and vasoconstrictors showed that improvement in
renal function in cirrhosis only occurs when both procedures are
applied simultaneously [33]. In our ﬁrst study we used ornipres-
sin and HSA [1 g/kg b.wt. on the ﬁrst day followed by 20 to 40 g/
day] [34]. A remarkably improvement in circulatory function was
observed with rapid suppression of the renin-angiotensin and
sympathetic nervous systems, progressive normalization in
serum creatinine and increase in renal perfusion and GFR
(Table 3). Because treatment was associated with ischemic events
in some patients, the study was repeated using i.v. terlipressin
(1–2 mg/4–6 h) with identical results but no ischemic complica-
tions [35].
Many studies have been subsequently published on the use of
terlipressin and albumin for HRS and their main conclusions are
the following: (1) Terlipressin plus HSA reverses type-1 HRS
(serum creatinine <1.5 mg/dl) in 40–65% of patients [36–38]. In
less than 20% of responders type-1 HRS recurs after discontinua-
tion of treatment but it may reverse again following retreatment.
(2) The rate of response may increase if terlipressin is given by
continuous infusion [39]. (3) Predictors of response include low
baseline serum creatinine (<5 mg/dl) and bilirubin (<10 mg/dl),
and increase in mean arterial pressure (>5 mm/Hg) within the
ﬁrst 3 days of treatment [40–42]. (4) Reversal of HRS is associated
with improvement in survival [43,44]. (5) Noradrenaline is as
effective as terlipressin [45–47]. (6) Reversal of type 1 HRS is sig-
niﬁcantly lower if terlipressin is given without HSA [48]. (7)
Type-1 HRS may reverse with HSA alone [49–51]. (8) Patients
with ongoing bacterial infections should be treated as soon as
type-1 HRS is diagnosed [52]. (9) Treatment is not indicated in
type-2 HRS because HRS recurrence is the rule [53].398 Journal of Hepatology 201Other potential indications for albumin in cirrhosis
Thereare fourstudiesassessing long-termadministrationofHSA in
cirrhosis with ascites. The rationale behind these investigations is
that long-term improvement of circulatory function may prevent
acute complications of cirrhosis, including recurrence of ascites,
HRS, encephalopathy, and bacterial infections. The ﬁrst investiga-
tion was a comparative study in 17 patients, 9 receiving between
184 to 558 g of HSA within 6 months [54]. All patients in the HSA
groupsurvivedformorethan2 years. In thecontrolgroupmortality
rate was 30%. The second study was a randomized controlled trial
(RCT) in 126 patients hospitalized for ascites [55]. Half of the
patients received diuretics and half diuretics plus HSA [12.5 g/day
during hospitalization, 25 g/week during the ﬁrst year and 25 g/
2 weeks during the second and third year]. Cumulative incidence
of acute complications and hospital admission was signiﬁcantly
lower in patients receiving albumin. There were no signiﬁcant dif-
ferences in survival. Two other studies are still ongoing. TheMUCH
study (ClinicalTrials.gov, Identiﬁer: NTC00839358) is a RCT com-
paring standard therapy vs. standard therapy, HSA (40 g every
2 weeks) and midodrine (an oral a-adrenergic agonist) in 190
patients with ascites. The main end-points of the study are
incidence of complications and survival. The ANSWER study4 vol. 61 j 396–407
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Fig. 2. Molecular structure of human serum albumin. Crystal structure (pdb
code 1e7i) of HSA with an indication of the its subdomains (IA, IB, IIA, IIB, IIIA an
IIIB), of the N and C termini, of Sudlow’s sites I and II and of the seven LCFA
binding sites (FA1 to FA7). The heavy atoms of the side chain of residue Cys-34
are shown as purple spheres. LCFA binding sites also bind prostaglandins. Cys-34
binds ROS and RNS, including NO [61].(ClinicalTrials.gov, Identiﬁer: NTC01288794) is a RCT in 400
patients with ascites comparing standard therapy vs. standard
therapyplusHSA(40 gtwiceweekly in theﬁrst twoweeksandonce
weekly for one year). The main end points are mortality and inci-
dence of refractory ascites.
The use of HSA for the management of non-SBP bacterial infec-
tions is an increasing indication in Europe (Table 1). There is data
that these patients also develop type-1 HRS [25,22]. On the other
hand a recent RCT in 110 patients (INFECIR-1 Study) showed that
HSA [1.5 g/kg b.wt. at infection diagnosis and 1 g/kg b.wt. at the
third day] has beneﬁcial effects on renal and circulatory function
[56]. A trend for better prognosis inpatients receivingHASwas also
observed. A second RCT (INFECIR-2 study, ClinicalTrials.gov, Iden-
tiﬁer: NTC02034279) has been started by the EASL Chronic Liver
Failure Consortium; 512 patientswith non SBP bacterial infections
and high risk of type-1 HRS and death will be included.
Key Points 1
• HSA is an extracellular hearth-shaped three-domain 
protein of intermediate size (6.8×104 g/mol) that is 
synthesized in the liver and is the most abundant 
protein in plasma. It is a protein of remarkable solubility 
(50 mg/ml) owing to its high content (30%) in charged 
residues (39 Asp, 60 Glu, 58 Lys, 23 Arg) and performs 
a wide range of functions ranging from regulating 
oncotic pressure to scavenging reactive oxygen 
species. Both the amount and quality of HSA are 
important for health
• The structure of HSA, solved at high resolution in 1992, 
is stabilized by a remarkably large (17) number of 
intra-domain disulfide bonds that render the individual 
domains, that are of similar size and structure, very 
stable. Domains I and III, which are lobes in the 
structure, can fold autonomously but domain II, which is 
the core of the structure of HSA, cannot. This structural 
coupling provides a framework for the allosteric 
regulation of HSA, whereby the binding of ligands or 
chemical modifications in one domain generates a 
signal that can propagate to a different domain
• At the molecular level the most striking feature of HSA 
is its ability to bind to a wide range of ligands, which 
is intimately linked with one of its physiological roles, 
to transport relatively hydrophobic species that 
would otherwise not be soluble in plasma. This 
includes small molecules such as hormones, fatty 
acids, bilirubin and heme as well as metals such as 
Cu, Fe and Hg but also more complex substances 
such as lipopolysaccharide. In addition to endogenous 
ligands HSA can also bind to exogenous ligands such 
as drugs, greatly contributing to their bioavailability
• HSA can be modified irreversibly by non-enzymatic 
glycosylation of Lys side chains, mainly Lys525, as well 
as by oxidation, mainly of the only free Cys residue 
in the protein, Cys34. The former occurs in diabetic 
patients whereas the latter is frequent in acute on 
chronic liver failure. Although the mechanisms by 
which these chemical modifications alter the structural 
properties of HSA are not known there is substantial 
evidence that they alter the physiological functions of 
the protein, presumably by collective changes in its 
structureJournal of Hepatology 201Chemistry and physiology of HSAJOURNAL OF HEPATOLOGYMolecular structure and chemical propertiesHSA is a multi-domain protein stabilized by 17 disulﬁde bonds
that confer a remarkable stability to its structure [57]. In addition
to the 34 cysteine residues involved in disulﬁde bonds HSA also
possesses a free cysteine (Cys-34) that is relatively solvent-
exposed (Fig. 2) and plays an important role in its antioxidant
activity [58,59]. The structure of HSA at low resolution (6 Å)
was ﬁrst solved in 1989 [60] and a high resolution atomic struc-
ture (2.8 Å) was reported in 1992 [57]. These revealed this pro-
tein to be composed of three domains of similar size (residues
1–197, 198–381, and 381–585) arranged in a heart shape and
formed by eight a-helices. Owing to their structural similarity
the domains can be divided in sub-domains (IA, IB, IIA, IIB, IIIA,
and IIIB) that have functional relevance as they deﬁne the binding
sites of many HSA ligands (Fig. 2) [61].
Due to the presence of a substantial number of intra-domain
disulﬁde bonds the domains of HSA have signiﬁcant stability.
Domains I and III are particularly stable and a construct contain-
ing domains I and II [1–381] as well as a construct containing
domains II and III [198–585] fold autonomously by adopting
the same structure that they have in the full-length protein
[62,63]. In spite of its large size and owing to its remarkable sta-
bility and its relatively simple structure, where residues that are
connected by disulﬁdes or in contact are not particularly distant
in sequence, HSA can be refolded from the fully reduced state
unassisted by molecular chaperones [64,65]. This greatly facili-
tates its synthesis in the laboratory and the study of its structural
and biophysical properties [62].
Again owing to its relatively simple structure and modular
nature HSA appears to be a very ﬂexible protein. According to4 vol. 61 j 396–407 399
Key Points 2
• The total extracellular pool of albumin of a 70 kg b.wt. 
healthy man is 360 g  which represents 3.2 x 1021 
molecules of albumin. The weight of the extracellular 
pool of albumin is similar to the total liver protein 
weight. 66% of the extracellular albumin is in the 
interstitial space and 33% in the intravascular space. 
The transfer of albumin from the intravascular to 
the interstitial space (transcapillary escape rate of 
albumin) is 4-5% per hour and approximately the 
same percentage is returned to the intravascular 
compartment throughout the lymphatic system; 80% of 
the extravascular pool is in the muscle and skin
• Albumin is synthesized only by the hepatocytes and 
it is not stored, rather the protein is rapidly secreted 
(synthesis occurs within 2-3 minutes and secretion 
within 25 minutes). Each hepatocyte synthesizes 
approximately 15 x 106 albumin molecules per minute 
which represents a total hepatic synthesis of 13-14 
g (3.5% of the total albumin pool) per day of newly 
synthesized albumin entering the intravascular space.  
An equivalent mass of albumin is catabolized. The 
half life of albumin is 19 days. An average molecule, 
therefore, leaves the circulation every 23 h, which 
means approximately 28 trips from and back to the 
circulation during its lifetime, and makes around 15,000 
trips around the circulation
 
• The plasma concentration of albumin (35-45 g/L) and 
the total albumin pool are regulated by changes in 
albumin gene transcription and in albumin catabolism. 
The most important physiological factor regulating 
synthesis is the plasma concentration of albumin. 
Hypoalbuminemia stimulates albumin synthesis. 
Conversely, albumin infusion depresses albumin 
synthesis. The administration of other macromolecules 
(dextrans) has similar effects pointed to the colloid 
osmotic pressure as the function on which this 
regulation is based. Albumin catabolism is regulated 
by the total albumin pool. A decrease in albumin pool 
leads to a reduced albumin catabolism. Changes in 
albumin synthesis are less pronounced than changes 
in catabolism
• In patients with decompensated cirrhosis, albumin 
metabolism is much more complex than in healthy 
subjects, since there are additional mechanisms 
affecting synthesis and catabolism. For example, 
systemic inflammation is associated to a marked 
fall in albumin synthesis, a process that is mediated 
by cytokines (IL-6 and TNFα). On the other hand, 
structural changes of the albumin molecule related 
to specific binding of ligands (i.e., glucose, reactive 
oxygen or nitrogen species) are associated to rapid 
degradation and catabolism of the modified molecules.  
Since these processes are present in patients 
with decompensated cirrhosis or ACLF, albumin 
replacement requires high doses in these patients.  In 
fact, the amount of albumin given to a patient of 70 kg 
b.wt. with SBP (1.5 g/kg b.wt. at infection diagnosis and 
1 g/kg b.wt. at the third day) represents 48.6% of the 
total extracellular pool of albumin
Review
various experimental approaches the heart shape that the protein
adopts in the crystal is likely to be only one in the range of inter-
domain orientations that HSA samples show in solution. Experi-
ments monitoring the rate of exchange between exchangeable
hydrogens and water have shown these to be particularly labile,
indicating that in addition to inter-domain motions HSA under-
goes local unfolding events where the hydrogen bonds that stabi-
lize its secondary structure are transiently disrupted [66].
Many of the physiological functions of HSA rely on its ability
to reversibly bind to an extremely wide range of ligands to
increase their solubility in plasma, to transport them to speciﬁc
tissues or organs or to dispose of them when they are toxic.
The structures of HSA bound to various of these substrates have
been determined by X-ray crystallography, revealing that on
many occasions the protein must experience substantial struc-
tural changes to accommodate the ligand and therefore strongly
suggesting a functional role for its high ﬂexibility. Although many
binding sites for ligands have been reported in HSA the most
important sites are commonly known as Sudlow’s sites I and II
(Fig. 2) which are found in subdomains IIA and IIIA, respectively.
Long chain fatty acids (LCFAs) are intermediates in lipid
metabolism that circulate in plasma both in soluble form as well
as associated with HSA. According to crystallographic studies
they can bind up to seven sites in HSA (FA1 to FA7) including
both Sudlow’s sites, with site I corresponding to FA7 and site II
corresponding to FA3 and FA4 [67]. It is however likely that many
of these sites are secondary and therefore do not play an impor-
tant role in LCFA binding in physiological conditions, where it is
thought that up to two LCFA molecules, bound to Sudlow’s site I,
are bound to HSA at a given time.
Drugs such as warfarin, indomethacin, ibuprofen, diazepam
are another heavily studied class of HSA ligands. Similarly to
what is the case for LCFAs these molecules can bind to various
sites in HSA and, although they tend to mainly interact with Sud-
low’s sites I and II, this can vary depending on the relative con-
centration of competing ligands and on the allosteric effects
discussed below [68]. That these and other drugs can compete
for HSA binding sites for their transport in plasma emphasizes
the importance of understanding the physicochemical basis of
their interaction with HSA [69].
Given that HSA is a ﬂexible protein that can bind to various
substrates in different sites there have been suggestions that it
is an allosteric protein, i.e., that its afﬁnity for speciﬁc ligands
can depend on whether a second ligand is occupying a different
binding site. Speciﬁc examples of such a behavior, among others,
include an allosteric coupling between the binding sites of heme
that binds to FA1 in sub-domain IB, and the drug warfarin, that
binds to Sudlow’s site I [70]. The structural, dynamical, and ther-
modynamic coupling between domains occurring in HSA is
highly suggestive of this possibility as these are sufﬁcient condi-
tions to give rise to allosteric binding [71].
Given its high stability HSA has a long half-life in plasma, of
about 19 days [2]. During this relatively long time its chemical
structure can be altered by oxidation as well as by non-enzymatic
glycosylation, among other irreversible modiﬁcations. The accu-
mulation of chemically altered HSA has been linked to speciﬁc
pathologies such as cirrhosis [72] and diabetes [73]. The highly
ﬂexible nature of this protein and the growing body of evidence,
suggesting that the various binding sites that contribute to HSA
function are strongly coupled, suggests that such chemical
alterations can have functional consequences. In this scenario400 Journal of Hepatology 2014 vol. 61 j 396–407
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the oxidation or glycosylation of speciﬁc positions in the surface
of HSA would cause structural changes that could propagate to
different regions of structure either by concerted conformational
changes or through local changes in the stability known to give
rise to long range effects in simpler systems.
The best studied irreversible alteration of the structure of HSA
is the oxidation by reactive oxygen species of Cys-34 from mer-
capto-albumin, which has the native thiol group, to non-mer-
capto-albumin, where the Cys side chain is involved in a
disulﬁde bond with either glutathion or another HSA molecule
[58,59]. The reaction can proceed further to the sulﬁnic and sul-
fonic acid derivatives of the side chain. An obvious consequence
of this reaction is a decrease in the anti-oxidant properties of
HSA, that rely on the thiol form of Cys-34, but there is also evi-
dence that it can indirectly lead to decreases in other functions
of HAS, such as its ability to bind drugs in Sudlow’s sites [72,74].
Physiology
Synthesis and metabolism
Albumin is synthesized by the liver and rapidly released to the
intravascular compartment [2]. The total amount of albumin in
humans is approximately 360 g, 120 being in the intravascular
and 240 in the extravascular compartment. Intravascular albu-
min is constantly being exchanged (4–5%/h) through the endo-
thelium with the extravascular pool. In organs having sinusoids
or capillaries with fenestrated endothelium albumin can pass
through the large capillary gaps. In the remaining capillaries with
continuous endothelium, albumin is transported by an active
transcytotic mechanism mediated by the gp60 receptor (albon-
din) [75–78]. There is a second group of receptors (gp18 and
gp30) expressed in many tissues that governs degradation of
albumin [78–81]. These surface cell receptors shows 1000-fold
higher afﬁnity for chemically modiﬁed albumin (i.e., oxidized
albumin). Once internalized, this modiﬁed albumin is degraded.
Finally, a third type of albumin receptor (FcRn) that rescues albu-
min from lysosomal degradation contributes to extend the albu-
min half life [78,82–84].
Physiology
The effects of HSA rely in the following features: an appropriated
molecular mass and negative charge generate high oncotic pres-
sure; a high solubility in water and density of binding sites make
the protein an ideal vehicle to transport water-insoluble sub-
stances; the effects of active exogenous and endogenous sub-
stances are modulated following binding to HSA; the high
extracellular concentration of HSA magniﬁed its biological
actions.
Among the substances transported, fatty acids stand up. HSA
is the main fatty acid binding protein in the extracellular space.
It carries fatty acids from the intestines to the liver and from
the liver to muscle and to and from adipose tissues [85,86].
Transportation of unconjugated bilirubin from the spleen or bone
marrow to the liver is the best example of albumin transportation
of a water insoluble endogenous metabolite to its elimination site
[87]. Other endogenous substances that bind to albumin are the
eicosanoids, bile acids, steroids, hematin, tiroxin, vitamin D, and
folate [2,88]. Among the exogenous molecules transported by
albumin there is a wide variety of drugs [2,69,89]. In addition
to drug solubility, albumin binding decreases toxicity and
increases drug half-life [69]. Drug binding to HSA can be affectedJournal of Hepatology 201by other drugs that compete with speciﬁc sites in the molecule.
As a consequence, an increase in the free fraction may lead to
changes in pharmacokinetics and pharmacodynamics. Drug-
albumin binding may be also altered in diseased states, including
liver and renal diseases [58,90,91], due to the increase in endog-
enous substances that compete for binding sites, but pharmaco-
kinetic consequences of this does rarely cause important effects
[92,93].
An outstanding feature of HSA is its capacity to bind pro-
inﬂammatory substances and mediators of inﬂammation. Lipo-
polysaccharide (LPS), lipoteichoic acid, and peptidoglycan are
surface components of gram-negative and gram-positive bacteria
that activate the innate immune system through Toll-like recep-
tor 4 (TLR4) and induce inﬂammation. HSA binds these molecules
by electrostatic and hydrofobic forces [94–97]. Cell activation by
LPS requires an ordered interaction with several host proteins
including LPS-binding protein, CD14 and co-receptor MD-2.
Recent studies showed that albumin may also participate in LPS
presentation to TLR4 facilitating disaggregation of LPS-Lipid A
polymers and donation of monomers to CD14 [98–100]. This sug-
gests that albumin promotes the inﬂammatory response. In con-
trast, LPS-albumin complexes are much less effective in immune
activation than endotoxin-CD14 complexes [100]. Giving the
abundance of albumin and the lower relative cell activation
capacity of the LPS-albumin complex, albumin could play a role
in moderating the inﬂammatory response to bacterial infections.
Therefore, albumin could play a dual role either stimulating or
moderating immune cells activation depending on pathophysio-
logical conditions [98,100].
Systemic inﬂammatory response can be triggered by antigens
derived from bacteria (Pathogens-Associated Molecular Patterns,
PAMPs) or by intrinsic factors released into the circulation as a
result of trauma or cell injury (Damaged Associated Molecular
Patterns, DAMPs). Specialized receptors of the innate immune
system recognized these factors and release inﬂammatory medi-
ators among which cytokines, and reactive oxygen (ROS) and
nitrogen species (RNS) are the most important [101,102]. Gener-
ation of ROS and RNS (superoxide, nitric oxide, hydrogen perox-
ide, hydroxyl radical, peroxynitrite, hypochlorous acid, nitrogen
dioxide radical, hydroperoxide radical, and peroxyl radical) by
neutrophils, macrophages, and endothelial cells, which represent
the innate immune system, is the ﬁrst line of defense against sep-
sis [103–105]. The aim of the modiﬁcation of the redox state in
plasma and extracellular ﬂuid is to destroy the bacteria by energy
depletion and oxidative damage of lipids, proteins, and DNA. This
extracellular oxidative ‘‘burst’’ however may be transferred into
mitochondria leading to cell dysfunction and organ failure
[103]. Extracellular ﬂuid and the mitochondria dispose of antiox-
idant systems to prevent excessive oxidative damage [103–105].
HSA is the main extracellular defense against oxidative stress. It
provides 80% of extracellular thiols, which are potent scavengers
of ROS and RNS [60,106,107]. The glutathione system is the most
abundant mitochondrial antioxidant. Intracellular albumin catab-
olism represents a source of sulfur-containing amino acids for the
synthesis of glutathione. Albumin therefore modulates the intra-
cellular levels of this antioxidant system [108].
Two mechanisms account for the antioxidant effect of HSA.
The ﬁrst is related to its capacity to bind and inactivate free met-
als such as cooper and iron, which catalyse the formation of
aggressive ROS [109,110]. HSA-bound bilirubin inhibits lipid per-
oxidation and represents an indirect antioxidant effect [111]. The4 vol. 61 j 396–407 401
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second and most important mechanism is related to the capacity
of HSA to trap free radicals. Two-thirds of the HSA molecules
exist in a reduced form with a free thiol group in the Cys-34 res-
idue. Working as a free radical scavenger, the Cys-34 residue is
able to trap multiple ROS and RNS [60,107]. As indicated, in phys-
iological conditions the Cys-34 residue exists in two different
forms, namely human-mercapto-albumin (HMA; reduced) in
which the thiol group is in the free state and human non-mer-
capto albumin (NMA; oxidized) [60,107,112]. In this later form
the thiol group may be present as a disulﬁde that is formed
reversibly with Cys or glutathione or as sulﬁnic or sulfonic acid
that is formed irreversibly. Irreversible albumin oxidation is asso-
ciated with a loss of function and rapid degradation. Cys-34 is a
good indicator for evaluating oxidative stress in the systemic cir-
culation [60,107]. HSA contains six methionine residues which
can also be oxidized [112,113].
Under nitrosative stress by nitric oxide (NO) or other nitrosy-
lating agents, mercaptalbumin can be converted in nitroso-HSA.
This is a reversible reaction, so that NO can be transferred to
other molecules [114,115]. HSA also binds arachidonic acid, pros-
taglandins, thomboxanes, and leukotrienes [116–120]. HSA has
two-sided effects on eicosanoids. In some cases the protein,
which has intrinsic enzymatic activity, catalyzes their synthesis
or degradation. In others (i.e., PGI2, thromboxanes, and leukotri-
enes) it stabilizes the molecule by delaying hydrolysis. HSA,
therefore, functions as storage, carrier, and supplier of NO and
eicosanoids to target sites to initiate physiological actions (vaso-
dilation and inhibition of platelet aggregation) and as protector
agents to diminish harmful biological effects if produced in too
large amounts. By these mechanisms HSA modulates endothelial
function and inﬂammation.Decompensated cirrhosis is associated with systemic
inﬂammation
Three major features characterize decompensated cirrhosis. The
ﬁrst is multi-organ dysfunction. The second is a systemic inﬂam-
matory reaction with increased plasma and ascitic ﬂuid concen-
tration of cytokines and C-reactive protein (CRP) [121–129].
Finally, the third is an increased systemic oxidative stress with
a high levels of oxidized HSA and of other markers of oxidative
stress [58,72]. Systemic inﬂammation, oxidative stress, and organ
dysfunction are moderate in patients with decompensated cir-
rhosis and severe in patients with acute-on-chronic liver failure
(ACLF) [1,130] (Fig. 3). Translocation of bacterial products (i.e.,
lipopolysaccharide, bacterial DNA) or of viable organisms from
the intestinal lumen to the circulation due to quantitative and
qualitative changes in gut microbiota, impairment in intestinal
mucosal barrier, increased epithelial permeability, and impaired
intestinal immunity, are important mechanisms of systemic
inﬂammation in cirrhosis [1,23,26,130,131]. However, systemic
inﬂammation may also occur in response to acute liver injury
(i.e., acute alcoholic hepatitis) or other mechanisms [1].
Closed interactions exist between bacterial translocation,
local inﬂammation, and cardiovascular dysfunction in decompen-
sated cirrhosis (Fig. 3). Activation of the intestinal immune sys-
tem by bacterial translocation causes local release of NO and
other vasodilators leading to the characteristic hyperdynamic cir-
culation of cirrhosis and in more advanced stages, effective hyp-
ovolemia, activation of the renin-angiotensin system (RAS),402 Journal of Hepatology 201sympathetic nervous systems (SNS) and antidiuretic hormone
(ADH), and ascites formation [28,130–134]. On the other hand,
the activated sympathetic nervous system induces changes in
the gut microbiota and impairs intestinal immunity, thus produc-
ing a vicious circle promoting the progression cardiovascular dys-
function [131]. A slow but progressive impairment of left
ventricular function and cardiac output also develops in decom-
pensated cirrhosis and contributes to circulatory dysfunction
[135,136]. Recent data suggest that impairment in cardiac func-
tion in experimental cirrhosis is related to inﬂammation,
tumor-necrosis factor a (TNFa)-related activation of inducible
NO-synthase and oxidative stress in the cardiac tissue [137].
ACLF is characterized by acute development of organ failure(s)
(liver, renal, brain, coagulation, circulation, respiration) in
patients with compensated or decompensated cirrhosis [1]. ACLF
develops in the setting of severe systemic inﬂammatory reaction
due to bacterial infection, acute alcoholic hepatitis or other pre-
cipitating events [1,23]. The number of organ failures correlates
directly with the degree of systemic inﬂammation (Fig. 4) [1].
Therefore, whereas systemic inﬂammation is chronic and moder-
ate in decompensated cirrhosis, it is acute and severe in ACLF
(Fig. 4). The mechanism of organ failure in ACLF is complex
(Fig. 3). Acute impairment in cardiovascular function leading to
intense organ hypoperfusion is a major feature [21]. However
recent studies in sepsis suggest that extension of systemic
inﬂammation to organs leading to abnormal distribution of blood
ﬂow within the microcirculation and cell dysfunction related to
mitochondrial oxidative stress are also important mechanisms
[138,139].
Bacterial infection is a frequent precipitating event of hepatic
encephalopathy. Peripheral inﬂammation may affect cerebral
function through afferent vagal nerves activated by cytokines at
the site of inﬂammation, by lipopolysaccharide or cytokines that
interact to brain in areas lacking the blood-brain-barrier or by
diffusion to the brain of endothelial mediators [140–144]. Activa-
tion of microglia and synthesis of pro-inﬂammatory cytokines in
the brain have also been demonstrated in experimental models of
liver failure [141]. Circulatory dysfunction in patients with sys-
temic inﬂammation reduces brain perfusion [145]. Finally, sys-
temic inﬂammation increases the inhibitory effect of ammonia
in brain function [146,147]. There are marked differences in
hepatic encephalopathy between patients with decompensated
cirrhosis and patients with ACLF [148,149]. In the ﬁrst group
hepatic encephalopathy is of low grade and diuretics the most
frequent precipitating event. In contrast, hepatic encephalopathy
in ACLF is severe and bacterial infections or acute liver injury the
main precipitating factor. Organ dysfunction in cirrhosis there-
fore varies according to the mechanism and degree of systemic
inﬂammation.HSA may have therapeutic effects unrelated to volume
expansion
Considering the potential role of systemic inﬂammation in cir-
rhosis and the effect of HSA modulating the innate immune
response and oxidative stress, it is rational to suggest that some
effects of HSA (i.e., prevention and treatment of type-1 HRS)
might be related to these features. Indeed, there are many steps
in the process of acute decompensation of cirrhosis and ACLF that
could be inﬂuenced by HSA (Fig. 3). There are three studies sup-
porting this contention.4 vol. 61 j 396–407
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Fig. 3. Role of inﬂammation in the pathogenesis of decompensated cirrhosis and ACLF. Hypothesis on the role of inﬂammation in decompensated cirrhosis (left panel). The initial event is inﬂammation of the intestinal
submucosa and arterial vasodilation related to bacterial translocation. As the disease progresses effective arterial hypovolemia develops leading to stimulation of the RAS, SNS and antidiuretic hormone (ADH). The SNS
reduces intestinal motility, increases bacterial overgrowth and inhibits the intestinal immune system, worsening bacterial translocation and closing the ﬁrst vicious circle that perpetuates circulatory dysfunction. The
second vicious circle includes the extension of local inﬂammation to the systemic circulation and the organs. The ﬁnal effects are the complications associated with decompensated cirrhosis. The red boxes point out the
steps that may be inﬂuenced by HSA. Hypothesis on the role of inﬂammation in ACLF (right panel). ACLF is the result of a severe acute systemic inﬂammation secondary to PAMPs or DAMPs. Two types of processes then
develop. The ﬁrst is a rapid and severe impairment in systemic vascular resistance and left ventricular function leading to organ hypoperfusion. The second is the extension of systemic inﬂammation and oxidative stress to
the organs leading to abnormal distribution in blood ﬂow within the microcirculation and cell dysfunction. Both features lead to organ failure(s) and ACLF. The red boxes point out the steps that may be inﬂuenced by HSA.
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Fig. 4. Relationship between systemic inﬂammation and ACLF grade. Leuko-
cyte count and C-reactive protein in patients with decompensated cirrhosis (no
ACLF) and in patients with ACLF-1 (renal failure or single non renal organ failure
associated with renal dysfunction or moderate hepatic encephalopathy; for
further explanation see reference [1], ACLF-2 [2] organ failures) and ACLF-3 [3] or
more organ failures. Normal values of C-reactive protein are below 5 mg/L.
⁄p <0.05; ⁄⁄p <0.001 with respect to no ACLF. Results obtained from the CANONIC
data-base [1].
Key Points 3
• HSA is one of the most frequent treatments in 
patients with decompensated cirrhosis. Prevention 
of paracentesis-induced circulatory dysfunction, 
prevention of type-1 HRS associated to SBP 
and treatment of type-1 hepatorenal syndrome 
are the main indications. In patients with these  
indications HSA improves survival
• The effects of HSA rely on the following features: its 
relatively large molecular mass and the negative 
charge of the molecule generate high oncotic pressure; 
a high solubility in water and density of binding sites 
make the protein an ideal vehicle to transport water-
insoluble substances; the effects of exogenous and 
endogenous substances are modulated following 
binding to HSA; the high extracellular concentration of 
HSA magnifies its biological actions
• Decompensated cirrhosis is associated to moderate 
and chronic systemic inflammation, which plays 
an important role in the pathogenesis of acute 
decompensation and organ/system dysfunction. 
Systemic inflammation is related to translocation of 
bacterial products from the intestinal lumen to the 
submucosal space and the systemic circulation
• In contrast, systemic inflammation in patients with 
ACLF, a syndrome characterized by decompensated 
cirrhosis and organ failure(s), is acute, severe 
and frequently related to spontaneous bacterial 
infections (spontaneous bacteremia and SBP) due to 
translocation of viable bacteria. Systemic inflammation 
in ACLF may be also due to other types of infection 
and acute liver injury (i.e., acute alcoholic hepatitis)
  
• The therapeutic action of HSA in cirrhosis is probably 
related not only to expansion of the plasma volume 
but also to a modulation of systemic and organ 
inflammation
Review
404 Journal of Hepatology 201Two studies compared the systemic hemodynamic changes in
uncomplicated patients with SBP treated with albumin or
hydroxyethyl starch [150,151]. Circulatory function only
improved in patients receiving albumin. An increase in left ven-
tricular function, cardiac output, and peripheral vascular resis-
tance was observed, indicating a simultaneous effect of HSA in
the heart and in the peripheral circulation. An effect of HSA mod-
ulating the cardiac and endothelial effect NO was proposed to
explain the different circulatory response on the basis of distinct
changes in the plasma levels of NO metabolites and von Wille-
brand Factor between groups [152–154].
The third investigation was performed in cirrhotic rats with
ascites [135]. Plasma volume expansion with HSA but not with
hydroxyethyl starch improved left ventricular function ex vivo.
This effect was related to a normalization of activated protein
expression of TNFa and inducible NO synthase, MAD(P)H-oxidase
activity and nuclear translocation of NF-jB in cardiac tissue, indi-
cating a decrease of heart inﬂammation and oxidative stress.Conﬂict of interest
VA has a grant from Grifols. RG and XS declared that they do not
have anything to disclose regarding funding or conﬂict of interest
with respect to this manuscript. The EASL Chronic Liver Failure
Consortium has an unrestricted grant from Grifols.
Acknowledgements
We are grateful to the Esther Koplowitz Foundation for its
support.
References
[1] Moreau R, Jalan R, Ginès P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-
chronic liver failure is a distinct syndrome that develops in patients with
acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437.
[2] Peters Jr T. All about albumin. Biochemistry and medical applications. Inc
San Diego: Academic Press; 1966.
[3] Thorn GW, Armstrong Jr SH, Davenport VD. Chemical, clinical, and
immunological studies on the products of human plasma fractionation.
XXXI. The use of salt-poor concentrated human serum albumin solution in
the treatment of hepatic cirrhosis. J Clin Invest 1946;25:304–323.
[4] Kunkel HG, Labby DH, Ahrens EH, Shank RE, Hoagland CL. The use of
concentrated human serum albumin in the treatment of cirrhosis of the
liver. J Clin Invest 1948;27:305–319.
[5] Faloon WW, Eckhardt RD, Lynch Murphy T, Cooper AM, Davidson CS. An
evaluation of human serum albumin in the treatment of cirrhosis of the
liver. J Clin Invest 1949;28:583–594.
[6] Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver
failure. Lancet 1956;271:1121–1125.
[7] Traverso H, Vesin P, Combrisson A, Besson P, Cattan R. Intravenous albumin
loading in ascitic cirrhosis. Biological study. Sem Hop 1964;40:17–20.
[8] Wapnick S, Grosberg S, Kinney M, Azzara V, LeVeen HH. Renal failure in
ascites secondary to hepatic, renal, and pancreatic disease. Treatment with
a LeVeen peritoneovenous shunt. Arch Surg 1978;113:581–585.
[9] Ginès P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison
of paracentesis and diuretics in the treatment of cirrhotics with tense
ascites. Results of a randomized study. Gastroenterology 1987;93:234–241.
[10] Titó L, Ginès P, Arroyo V, Planas R, Panés J, Rimola A, et al. Total paracentesis
associated with intravenous albumin management of patients with
cirrhosis and ascites. Gastroenterology 1990;98:146–151.
[11] Arroyo V, Ginès A, Saló J. A European survey on the treatment of ascites in
cirrhosis. J Hepatol 1994;21:667–672.
[12] Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panés J, et al. Paracentesis
with intravenous infusion of albumin as compared with peritoneovenous
shunting in cirrhosis with refractory ascites. N Engl J Med 1991;325:
829–835.4 vol. 61 j 396–407
JOURNAL OF HEPATOLOGY
[13] Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, et al. Randomized
comparative study of therapeutic paracentesis with and without intrave-
nous albumin in cirrhosis. Gastroenterology 1988;94:1493–1502.
[14] Planas R, Ginès P, Arroyo V, Llach J, Panés J, Vargas V, et al. Dextran-70 vs.
albumin as plasma expanders in cirrhotic patients with tense ascites
treated with total paracentesis. Results of a randomized study. Gastroen-
terology 1990;99:1736–1744.
[15] Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E,
Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and
polygeline in cirrhotic patients with ascites treated by paracentesis.
Gastroenterology 1996;111:1002–1010.
[16] Saló J, Ginès A, Ginès P, Piera C, Jiménez W, Guevara M, et al. Effect of
therapeutic paracentesis on plasma volume and transvascular escape rate
of albumin in patients with cirrhosis. J Hepatol 1997;27:645–653.
[17] Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés
J. Paracentesis-induced circulatory dysfunction: mechanism and effect on
hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579–586.
[18] Vila MC, Solà R, Molina L, Andreu M, Coll S, Gana J, et al. Hemodynamic
changes in patients developing effective hypovolemia after total paracen-
tesis. J Hepatol 1998;28:639–645.
[19] Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in
patients undergoing large-volume paracentesis: a meta-analysis of ran-
domized trials. Hepatology 2012;55:1172–1181.
[20] Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal
impairment after spontaneous bacterial peritonitis in cirrhosis: incidence,
clinical course, predictive factors and prognosis. Hepatology 1994;20:
1495–1501.
[21] Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo
A, et al. Systemic, renal, and hepatic hemodynamic derangement in
cirrhotic patients with spontaneous bacterial peritonitis. Hepatology
2003;38:1210–1218.
[22] Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal
failure and bacterial infections in patients with cirrhosis: epidemiology and
clinical features. Hepatology 2007;45:223–229.
[23] Navasa M, Follo A, Filella X, Jiménez W, Francitorra A, Planas R, et al. Tumor
necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in
cirrhosis: relationship with the development of renal impairment and
mortality. Hepatology 1998;27:1227–1232.
[24] Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, et al.
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous
bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:
1944–1953.
[25] Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, et al.
Renal failure and hyponatremia in patients with cirrhosis and skin and soft
tissue infection. A retrospective study. J Hepatol 2012;56:1040–1046.
[26] Byl B, Roucloux I, Crusiaux A, Dupont E, Devière J. Tumor necrosis factor
alpha and interleukin 6 plasma levels in infected cirrhotic patients.
Gastroenterology 1993;104:1492–1497.
[27] Ramírez MJ, Ibáñez A, Navasa M, Casals E, Morales-Ruiz M, Jiménez W, et al.
High-density lipoproteins reduce the effect of endotoxin on cytokine
production and systemic hemodynamics in cirrhotic rats with ascites. J
Hepatol 2004;40:424–430.
[28] SchrierRW,ArroyoV,BernardiM,EpsteinM,Henriksen JH,Rodés J. Peripheral
arterial vasodilation hypothesis: a proposal for the initiation of renal sodium
and water retention in cirrhosis. Hepatology 1988;8:1151–1157.
[29] Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence,
predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis
with ascites. Gastroenterology 1993;105:229–236.
[30] Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al.
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatore-
nal syndrome and improves survival in cirrhosis. Gastroenterology
2007;133:818–824.
[31] Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al.
Effect of intravenous albumin on renal impairment and mortality in
patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med
1999;341:403–409.
[32] Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of
patients with spontaneous bacterial peritonitis: a meta-analysis of ran-
domized trials. Clin Gastroenterol Hepatol 2013;11:123–130.
[33] Shapiro MD, Nicholls KM, Groves BM, Kluge R, Chung HM, Bichet DG, et al.
Interrelationship between cardiac output and vascular resistance as
determinants of effective arterial blood volume in cirrhotic patients.
Kidney Int 1985;28:206–211.
[34] Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez
W, et al. Reversibility of hepatorenal syndrome by prolonged administra-Journal of Hepatology 201tion of ornipressin and plasma volume expansion. Hepatology
1998;27:35–41.
[35] Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, et al.
Terlipressin plus albumin infusion: an effective and safe therapy of
hepatorenal syndrome. J Hepatol 2000;33:43–48.
[36] Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and
ascites. N Engl J Med 2004;350:1646–1654.
[37] Garcia-Tsao G, Lim JK. Members of Veterans Affairs Hepatitis C Resource
Center Program. Management and treatment of patients with cirrhosis and
portal hypertension: recommendations from the Department of Veterans
Affairs Hepatitis C Resource Center Program and the National Hepatitis C
Program. Am J Gastroenterol 2009;104:1802–1829.
[38] Ginès P, Angeli P, Lenz K, Møller S, Moore K, Moreau R, et al. EASL clinical
practice guidelines on the management of ascites, spontaneous bacterial
peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol
2010;53:397–417.
[39] Angeli P, Fasolato S, Cavallin M, Trotta E, Maresio G, Callegaro A, et al.
Terlipressin given as continuous intravenous infusion vs. terlipressin given
as intravenous boluses in the treatment of type 1 hepatorenal syndrome
(HRS) in patients with cirrhosis. J Hepatol 2009;50:S73.
[40] Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, et al. Predictors
of response to terlipressin plus albumin in hepatorenal syndrome (HRS)
type 1: relationship of serum creatinine to hemodynamics. J Hepatol
2011;55:315–321.
[41] Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatore-
nal syndrome parallels increase in mean arterial pressure: a pooled analysis
of clinical trials. Am J Kidney Dis 2011;58:928–938.
[42] Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M,
et al. Predictors of response to therapy with terlipressin and albumin in
patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology
2010;51:219–226.
[43] Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, et al.
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a
retrospective multicenter study. Gastroenterology 2002;122:923–930.
[44] Arroyo V, Fernández J. Management of hepatorenal syndrome in patients
with cirrhosis. Nat Rev Nephrol 2011;7:517–526.
[45] Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT,
Martini S, et al. Noradrenalin vs. terlipressin in patients with hepatorenal
syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol
2007;47:499–505.
[46] Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized
controlled trial of noradrenaline vs. terlipressin in the treatment of type 1
hepatorenal syndrome and predictors of response. Am J Gastroenterol
2008;103:1689–1697.
[47] Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline
vs. terlipressin in the treatment of hepatorenal syndrome: a randomized
study. J Hepatol 2012;56:1293–1298.
[48] Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, et al.
Terlipressin therapy with and without albumin for patients with hepato-
renal syndrome: results of a prospective, nonrandomized study. Hepatol-
ogy 2002;36:941–948.
[49] Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, et al.
Terlipressin and albumin vs. albumin in patients with cirrhosis and
hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:
1352–1359.
[50] Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B,
et al. A randomized, prospective, double-blind, placebo-controlled trial of
terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:
1360–1368.
[51] Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, et al.
Treatment of hepatorenal syndrome as deﬁned by the international ascites
club by albumin and furosemide infusion according to the central venous
pressure: a prospective pilot study. Am J Gastroenterol 2005;100:
2702–2707.
[52] Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, et al.
Terlipressin and albumin for type-1 hepatorenal syndrome associated with
sepsis. J Hepatol 2014;60:955–961, [pii: S0168-8278[14]00055-5, Epub
ahead of print].
[53] Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal
failure in cirrhotic patients: role of terlipressin in clinical approach to
hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:
1363–1368.
[54] Tarao K, Iwamura K. Inﬂuence of long-term administration of serum
albumin on the prognosis of liver cirrhosis in man. Tokai J Exp Clin Med
1983;8:71–78.4 vol. 61 j 396–407 405
Review
[55] Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M,
et al. Albumin improves the response to diuretics in patients with cirrhosis
and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:
639–645.
[56] Guevara M, Terra C, Nazar A, Solà E, Fernández J, Pavesi M, et al. Albumin
for bacterial infections other than spontaneous bacterial peritonitis in
cirrhosis. A randomized, controlled study. J Hepatol 2012;57:759–765.
[57] He XM, Carter DC. Atomic structure and chemistry of human serum
albumin. Nature 1992;358:209–215.
[58] Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L,
Stadlbauer V. Oxidative albumin damage in chronic liver failure: relation
to albumin binding capacity, liver dysfunction and survival. J Hepatol
2013;59:978–983.
[59] Anraku M, Chuang VTG, Maruyama T, Otagiri M. Redox properties of serum
albumin. Biochim Biophys Acta 2013;1830:5465–5472.
[60] Carter DC, He XM, Munson SH, Twigg PD, Gernert KM, Broom MB, et al.
Three-dimensional structure of human serum albumin. Science 1989;244:
1195–1198.
[61] Bhattacharya AA, Grüne T, Curry S. Crystallographic analysis reveals
common modes of binding of medium and long-chain fatty acids to HSA.
J Mol Biol 2000;303:721–732.
[62] Mao H, Gunasekera AH, Fesik SW. Expression, refolding, and isotopic
labeling of human serum albumin domains for NMR spectroscopy. Protein
Expr Purif 2000;20:492–499.
[63] Milojevic J, Melacini G. Stoichiometry and afﬁnity of the human serum
albumin-Alzheimer’s Ab peptide interactions. Biophys J 2011;100:183–192.
[64] Burton SJ, Quirk AV, Wood PC. Refolding human serum albumin at
relatively high protein concentration. Eur J Biochem 1989;179:379–387.
[65] Chen Z, He Y, Shi B, Yang D. Human serum albumin from recombinant DNA
technology: challenges and strategies. Biochim Biophys Acta 2013;1830:
5515–5525.
[66] Hvidt A, Wallevik K. Conformational changes in human serum albumin as
revealed by hydrogen-deuterium exchange studies. J Biol Chem 1972;247:
1530–1535.
[67] Bhattacharya AA, Grüne T, Curry S. Crystallographic analysis reveals
common modes of binding of medium and long-chain fatty acids to human
serum albumin. J Mol Biol 2000;303:721–732.
[68] Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S.
Structural basis of the drug-binding speciﬁcity of human serum albumin. J
Mol Biol 2005;353:38–52.
[69] Yamasaki K, Chuang VTG, Maruyama T, Otagiri M. Albumin-drug interaction
and its clinical implication. Biochim Biophys Acta 2013;1830:5435–5443.
[70] Fanali G, Pariani G, Ascenzi P, Fasano M. Allosteric and binding properties of
Asp1-Glu382 truncated recombinant human serum albumin – an optical
and NMR spectroscopic investigation. FEBS J 2009;276:2241–2250.
[71] Hilser VJ, Thompson EB. Structural dynamics, intrinsic disorder, and
allostery in nuclear receptors as transcription factors. J Biol Chem
2011;286:39675–39682.
[72] Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al.
Alterations in the functional capacity of albumin in patients with decom-
pensated cirrhosis is associated with increased mortality. Hepatology
2009;50:555–564.
[73] Furusyo N, Hayashi J. Glycated albumin and diabetes mellitus. Biochim
Biophys Acta 2013;1830:5509–5514.
[74] Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, et al.
Identiﬁcation and characterization of oxidized human serum albumin. A
slight structural change impairs its ligand-binding and antioxidant func-
tions. FEBS J 2006;273:3346–3357.
[75] Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin.
Differential role of receptors in endothelial transcytosis and endocytosis of
native and modiﬁed albumins. J Biol Chem 1994;269:6072–6082.
[76] Minshall RD, Tiruppathi Ch, Vogel SM, Malik AB. Vesicle formation and
trafﬁcking in endothelial cells and regulation of endothelial barrier
function. Histochem Cell Biol 2002;117:105–112.
[77] Malik AB. Targeting endothelial cell surface receptors: novel mechanisms
of microvascular endothelial barrier transport. J Med Sci 2009;2:13–17.
[78] Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-
life extension. Biochim Biophys Acta 2013;1830:5526–5534.
[79] Ghinea N, Fixman A, Alexandru D, Popov D, Hasu M, Ghitescu L.
Identiﬁcation of albumin-binding proteins in capillary endothelial cells. J
Cell Biol 1988;107:231–239.
[80] Schnitzer JE, Sung A, Horvat R, Bravo J. Preferential interaction of albumin-
binding proteins, gp30 and gp18, with conformationally modiﬁed albu-
mins. Presence in many cells and tissues with a possible role in catabolism.
J Biol Chem 1992;267:24544–24553.406 Journal of Hepatology 201[81] Schnitzer JE, Bravo J. High afﬁnity binding, endocytosis, and degradation of
conformationally modiﬁed albumins. Potential role of gp30 and gp18 as
novel scavenger receptors. J Biol Chem 1993;268:7562–7570.
[82] Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species
binding analyses of mouse and human neonatal Fc receptor show dramatic
differences in immunoglobulin G and albumin binding. J Biol Chem
2010;285:4826–4836.
[83] Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C.
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn)
using a minimal albumin binding domain. J Biol Chem 2011;286:
5234–5241.
[84] Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, Shauna M,
et al. Prolonged in vivo residence times of antibody fragments associated
with albumin. Bioconjug Chem 2001;12:750–756.
[85] Fujiwara S, Amisaki T. Fatty acid binding to serum albumin: molecular
simulation approaches. Biochim Biophys Acta 2013;1830:5427–5434.
[86] Van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab
Pharmacokinet 2009;24:300–307.
[87] Petersen CE, Ha CE, Harohalli K, Feix JB, Bhagavan NV. A dynamic model for
bilirubin binding to human serum albumin. J Biol Chem 2000;275:
20985–20995.
[88] Ha CE, Bhagavan NV. Novel insights into the pleiotropic effects of human
serum albumin in health and disease. Biochim Biophys Acta 2013;1830:
5486–5493.
[89] Wang ZM, Ho JX, Ruble JR, Rose J, Rüker F, Ellenburg M, et al. Structural
studies of several clinically important oncology drugs in complex with
human serum albumin. Biochim Biophys Acta 2013;1830:5356–5374.
[90] Klammt S, Wojak HJ, Mitzner A, Koball S, Rychly J, Reisinger EC, et al.
Albumin-binding capacity (ABiC) is reduced in patients with chronic kidney
disease along with an accumulation of protein-bound uraemic toxins.
Nephrol Dial Transplant 2012;27:2377–2383.
[91] Klammt S, Mitzner S, Stange J, Brinkmann B, Drewelow B, Emmrich J, et al.
Albumin-binding function is reduced in patients with decompensated
cirrhosis and correlates inversely with severity of liver disease assessed by
model for end-stage liver disease. Eur J Gastroenterol Hepatol 2007;19:
257–263.
[92] Fanali G, di Massi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human
serum albumin: from bench to bedside. Mol Aspects Med 2012;33:
209–290.
[93] Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo
efﬁcacy: misconceptions in drug discovery. Nat Rev Drug Discov 2010;9:
929–939.
[94] Jurgens G, Muller M, Garidel P, Koch MH, Nakakubo H, Blume A, et al.
Investigation into the interaction of recombinant human serum albumin
with Re-lipopolysaccharide and lipid A. J Endotoxin Res 2002;8:115–126.
[95] Fukui H. Relation of endotoxin, endotoxin binding proteins and macro-
phages to severe alcoholic liver injury and multiple organ failure. Alcohol
Clin Exp Res 2005;29:172S–179S.
[96] Dziarski R. Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysac-
charide-, and lipoteichoic acid-binding protein on lymphocytes and
macrophages. J Biol Chem 1994;269:20431–20436.
[97] David SA, Balaram P, Mathan VI. Characterization of the interaction of lipid
A and lipopolysaccharide with human serum albumin: implications for an
endotoxin carrier function for albumin. J Endotoxin Res 1995;2:99–106.
[98] Gioannini TL, Zhang D, Teghanemt A, Weiss JP. An essential role for albumin
in the interaction of endotoxin with lipopolysaccharide-binding protein
and sCD14 and resultant cell activation. J Biol Chem 2002;277:
47818–47825.
[99] Blomkalns AL, Stoll LL, Shaheen W, Romig-Martin SA, Dickson EW,
Weintraub NL, et al. Low level bacterial endotoxin activates two distinct
signaling pathways in human peripheral blood mononuclear cells. J
Inﬂamm (Lond) 2011;8:4.
[100] Esparza GA, Teghanemt A, Zhang D, Gioannini TL, Weiss JP. Endotoxin{mid-
dle dot}albumin complexes transfer endotoxin monomers to MD-2 result-
ing in activation of TLR4. Innate Immun 2012;18:478–491.
[101] Takeuchi O, Akira S. Pattern recognition receptors and inﬂammation. Cell
2010;140:805–820.
[102] Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al.
Alarmins: awaiting a clinical response. J Clin Invest 2012;122:2711–2719.
[103] Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-
organ failure. Virulence 2014;5:66–72.
[104] Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J
Anaesth 2011;107:57–64.
[105] Galley HF. Bench-to-bedside review: targeting antioxidants to mitochon-
dria in sepsis. Crit Care 2010;14:230.4 vol. 61 j 396–407
JOURNAL OF HEPATOLOGY
[106] Taverna M, Marie AL, Mira JP, Guidet B. Speciﬁc antioxidant properties of
human serum albumin. Anaesth Intensive Care 2013;3:4.
[107] Bruschi M, Candiano G, Santucci L, Ghiggeri GM. Oxidized albumin. The
long way of a protein of uncertain function. Biochim Biophys Acta
2013;1830:5473–5479.
[108] Cantin AM, Paquette B, Richter M, Larivée P. Albumin-mediated regulation
of cellular glutathione and nuclear factor kappa B activation. Am J Respir
Crit Care Med 2000;162:1539–1546.
[109] Bal W, Sokołowska M, Kurowska E, Faller P. Binding of transition metal ions
to albumin: sites, afﬁnities and rates. Biochim Biophys Acta 2013;1830:
5444–5455.
[110] Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free
Radic Biol Med 1995;18:321–336.
[111] Neuzil J, Stocker R. Free and albumin-bound bilirubin are efﬁcient co-
antioxidants for alpha-tocopherol, inhibiting plasma and low density
lipoprotein lipid peroxidation. J Biol Chem 1994;269:16712–16719.
[112] Bourdon E, Loreau N, Lagrost L, Blache D. Differential effects of cysteine and
methionine residues in the antioxidant activity of human serum albumin.
Free Radic Res 2005;39:15–20.
[113] Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative
stress. J Biol Chem 1997;272:20313–20316.
[114] Oettl K, Marsche G. Redox state of human serum albumin in terms of
cysteine-34 in health and disease. Methods Enzymol 2010;474:181–195.
[115] Raﬁkova O, Raﬁkov R, Nudler E. Catalysis of S-nitrosothiols formation by
serum albumin: the mechanism and implication in vascular control. Proc
Natl Acad Sci U S A 2002;99:5913–5918.
[116] Fitzpatrick FA, Liggett WF, Wynalda MA. Albumin-eicosanoid interactions.
A model system to determine their attributes and inhibition. J Biol Chem
1984;259:2722–2777.
[117] Kragh-Hansen U. Molecular and practical aspects of the enzymatic
properties of human serum albumin and of albumin-ligand complexes.
Biochim Biophys Acta 2013;1830:5535–5544.
[118] Yang J, Petersen CE, Ha CE, Bhagavan NV. Structural insights into human
serum albumin-mediated prostaglandin catalysis. Protein Sci 2002;11:
538–545.
[119] Wynalda MA, Fitzpatrick FA. Albumins stabilize prostaglandin I2. Prosta-
glandins 1980;20:853–861.
[120] Folco G, Granström E, Kindahl H. Albumin stabilizes thromboxane A2. FEBS
Lett 1977;82:321–324.
[121] Le Moine O, Soupison T, Sogni P, Marchant A, Moreau R, Hadengue A, et al.
Plasma endotoxin and tumor necrosis factor-alpha in the hyperkinetic
state of cirrhosis. J Hepatol 1995;23:391–395.
[122] Bac DJ, PruimboomWM, Mulder PG, Zijlstra FJ, Wilson JH. High interleukin-
6 production within the peritoneal cavity in decompensated cirrhosis and
malignancy-related ascites. Liver 1995;15:265–270.
[123] Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-
alpha correlate with severity of hepatic encephalopathy due to chronic
liver failure. Liver Int 2004;24:110–116.
[124] Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6
levels in patients with cirrhosis. Relationship to endotoxemia, tumor
necrosis factor-alpha, and hyperdynamic circulation. Scand J Gastroenterol
1996;31:500–505.
[125] Li CP, Lee FY, Tsai YT, Lin HC, Lu RH, Hou MC, et al. Plasma interleukin-8
levels in patients with post-hepatitic cirrhosis: relationship to severity of
liver disease, portal hypertension and hyperdynamic circulation. J Gastro-
enterol Hepatol 1996;11:635–640.
[126] Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G, et al. Serum
levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:
264–274.
[127] Genesca J, Gonzalez A, Segura R, Catalan R, Marti R, Varela E, et al.
Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of
patients with liver cirrhosis. Am J Gastroenterol 1999;94:169–177.
[128] Jain L, Sharma BC, Sharma P, Srivastava S, Agrawal A, Sarin SK. Serum
endotoxin and inﬂammatory mediators in patients with cirrhosis and
hepatic encephalopathy. Dig Liver Dis 2012;44:1027–1031.
[129] Montoliu C, Piedraﬁta B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, et al.
IL-6 and IL-18 in blood may discriminate cirrhotic patients with and
without minimal hepatic encephalopathy. J Clin Gastroenterol 2009;43:
272–279.
[130] Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al.
Increased lipopolysaccharide binding protein in cirrhotic patients with
marked immune and hemodynamic derangement. Hepatology 2003;37:
208–217.Journal of Hepatology 201[131] Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver
cirrhosis. J Hepatol 2014;60:197–209.
[132] Wiest R. Role of sympathetic nervous activity for bacterial translocation in
advanced experimental liver cirrhosis. Gastroenterol Hepatol 2011;34:
102–105.
[133] Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ.
Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO
production and impairs mesenteric vascular contractility. J Clin Invest
1999;104:1223–1233.
[134] Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver
diseases: from the patient to the molecule. Hepatology 2006;43:
S121–S131.
[135] Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al.
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology
2005;42:439–447.
[136] Krag A, Bendtsen F, Henriksen JH. S Møller2. Low cardiac output predicts
development of hepatorenal syndrome and survival in patients with
cirrhosis and ascites. Gut 2010;59:105–110.
[137] Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F, et al. Positive
cardiac inotropic effect of albumin infusion in rodents with cirrhosis and
ascites: molecular mechanisms. Hepatology 2013;57:266–276.
[138] Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. A
uniﬁed theory of sepsis-induced acute kidney injury: inﬂammation,
microcirculatory dysfunction, bioenergetics, and the tubular cell adapta-
tion to injury. Shock 2014;41:3–11.
[139] Merx MW, Weber C. Sepsis and the heart. Circulation 2007;116:793–802.
[140] Coltart I, Tranah TH, Shawcross DL. Inﬂammation and hepatic encepha-
lopathy. Arch Biochem Biophys 2013;536:189–196.
[141] Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inﬂammation and
ammonia in hepatic encephalopathy. Metab Brain Dis 2013;28:1–5.
[142] Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encepha-
lopathy: role of inﬂammation and oxidative stress. World J Gastroenterol
2010;16:3347–3357.
[143] Berg RM, Møller K, Bailey DM. Neuro-oxidative-nitrosative stress in sepsis.
J Cereb Blood Flow Metab 2011;31:1532–1544.
[144] Garcia-Martinez R, Cordoba J. Liver-induced inﬂammation hurts the brain. J
Hepatol 2012;56:515–517.
[145] Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, et al.
Increased cerebrovascular resistance in cirrhotic patients with ascites.
Hepatology 1998;28:39–44.
[146] Wright G, Davies NA, Shawcross DL, Hodges SJ, Zwingmann C, Brooks HF,
et al. Endotoxemia produces coma and brain swelling in bile duct ligated
rats. Hepatology 2007;45:1517–1526.
[147] Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inﬂammatory
response exacerbates the neuropsychological effects of induced hyperam-
monemia in cirrhosis. J Hepatol 2004;40:247–254.
[148] Shawcross DL, Shariﬁ Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al.
Infection and systemic inﬂammation, not ammonia, are associated with
Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol
2011;54:640–649.
[149] Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós A, Pavesi M, Vilstrup
H, et al. Characteristics, risk factors, and mortality of cirrhotic patients
hospitalized for hepatic encephalopathy with and without acute-on-
chronic liver failure (ACLF). J Hepatol 2014;60:275–281.
[150] Fernández J, Navasa M, Garcia-Pagan JC, G-Abraldes J, Jiménez W, Bosch J,
et al. Effect of intravenous albumin on systemic and hepatic hemodynamics
and vasoactive neurohormonal systems in patients with cirrhosis and
spontaneous bacterial peritonitis. J Hepatol 2004;41:384–390.
[151] Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, et al. A
randomized unblinded pilot study comparing albúmina vs. hydroxyethyl
starch in spontaneous bacterial peritonitis. Hepatology 2005;42:627–634.
[152] Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al.
Von Willebrand factor as new noninvasive predictor of portal hyperten-
sion, decompensation and mortality in patients with liver cirrhosis.
Hepatology 2012;56:1439–1447.
[153] Albornoz L, Alvarez D, Otaso JC, Gadano A, Salviú J, Gerona S, et al. Von
Willebrand factor could be an index of endothelial dysfunction in patients
with cirrhosis: relationship to degree of liver failure and nitric oxide levels.
J Hepatol 1999;30:451–455.
[154] Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM,
et al. High plasma levels of von Willebrand factor as a marker of
endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepa-
tology 1996;23:1377–1383.4 vol. 61 j 396–407 407
